Your location:Home page > Program
Mary Gulumian
Share on:
North West University

Bio: Prof. Mary Gulumian is a founder member and the past President of the Society for Free Radical Society of South Africa (SFRR–SA), a founder member and President of the Toxicology Society of South Africa (TOXSA) as well as Society of Risk Analysis (SRA)–Africa. She served as the Vice-President of the Executive Committee of the International Union of Toxicology (IUTOX). She was a member of the final review board of WHO Concise International Chemical Assessment Documents (CICAD) publications on toxic compounds. She currently represents South Africa in the OECD Working Party on Manufactured Nanomaterials and serves on Expert Technical Committee for WG3 of ISO/TC 229 on nanotechnologies. Nationally, in her capacity as the President of TOXSA, Professor Gulumian was involved in the registration of Toxicologists in South Africa and in setting up curricula necessary for this registration. She served as a Council member of the South African Council for Natural Scientific Professions (SACNASP) for 10 years and presently is a member of the Registration Committee. Professor Gulumian is the Specialty Chief Editor of Frontiers in Toxicology, and a member of the Editorial Board of Toxicology, and Particle and Fibre Toxicology, and the Associate Editor of Inhalation Toxicology.

 

Abstract: Chronic Inflammation is the major driver of most human diseases and can affect any organ system. Current research indicates that macrophages, which are present in most tissues, are central and phagocytosis of bioactive exogenous or endogenous particles. Bioactive particles bind to the inner lysosomal membrane, disrupting membrane architecture and sphingomyelin metabolism resulting in lysosome membrane permeability (LMP) which is the rate limiting step in inflammation. LMP results in the release of degradative enzymes into the cytosol and a subsequent cascade of events culminating in release of proinflammatory cytokines and cell injury. Due to the central role that LMP has in initiation of human diseases it is important to utilize validated tools to quantitate LMP. LMP is most often measured by quantitating the cytosolic presence of lysosomal enzymes through spectroscopic or fluorescent techniques. It is important to determine whether there is any potential interference in the assays from the presence of particles in cells that may under or overestimate LMP. Alternatively, measurements of initiation of disruption of membrane properties, downstream events such as activation of the NLRP3 inflammasome, reactive oxygen species production, or initiation of repair can help confirm initiation of LMP.


11

0

0

Date Time Local Time Room Forum Session Role Topic
2025-10-16 13:30-15:30 2025-10-16,13:30-15:30Room 1- Guobin Hall 1 Symposium Program (Session)

Session 01: The Serious Issue of Interference in Nanotoxicology

Chair
2025-10-16 14:30-15:00 2025-10-16,14:30-15:00Room 1- Guobin Hall 1 Symposium Program (Session)

Session 01: The Serious Issue of Interference in Nanotoxicology

Speaker Necessity of accurate assessment of the rate limiting step in initiation of inflammation